The devastating Ebola virus (EBOV) epidemic in West Africa in 2013–2016 accelerated the
progress of several vaccines and antivirals through clinical trials, including the replication …

The global outgoing outbreaks of Ebola virus disease (EVD) in different regions of Sudan,
Uganda, and Western Africa have brought into focus the inadequacies and restrictions of pre …

Background rVSV-ZEBOV is a recombinant, replication competent vesicular stomatitis virus-
based candidate vaccine expressing a surface glycoprotein of Zaire Ebolavirus. We tested …

Without an approved vaccine or treatments, Ebola outbreak management has been limited
to palliative care and barrier methods to prevent transmission. These approaches, however …

Background The worst Ebola virus disease (EVD) outbreak in history has resulted in more
than 28,000 cases and 11,000 deaths. We present the final results of two phase 1 trials of an …

A specific concept of strain was developed in order to classify the BTV serotypes ever
reported in Europe based on their properties of animal health impact: the genotype …

Ebola virus (EBOV), member of genus Ebolavirus, family Filoviridae, have a non-segmented,
single-stranded RNA that contains seven genes:(a) nucleoprotein (NP),(b) viral protein 35 …

Marburg virus (MARV) is a highly pathogenic virus associated with severe disease and
mortality rates as high as 90%. Outbreaks of MARV are sporadic, deadly, and often …

Recombinant vesicular stomatitis virus–Zaire Ebola virus (rVSV-ZEBOV) is the most
advanced Ebola virus vaccine candidate and is currently being used to combat the outbreak …

Vesicular stomatitis virus (VSV), which belongs to the Vesiculovirus genus of the family
Rhabdoviridae, is a well studied livestock pathogen and prototypic non-segmented …